Revvity (RVTY) Scheduled to Post Earnings on Monday

Revvity (NYSE:RVTY) will issue its quarterly earnings data before the market opens on Monday, April 29th. Analysts expect the company to announce earnings of $0.94 per share for the quarter. Revvity has set its FY 2024 guidance at 4.550-4.750 EPS and its FY24 guidance at $4.55-$4.75 EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Thursday, February 1st. The company reported $1.25 earnings per share for the quarter, topping analysts’ consensus estimates of $1.15 by $0.10. The company had revenue of $695.90 million for the quarter. Revvity had a net margin of 25.20% and a return on equity of 7.41%. On average, analysts expect Revvity to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Revvity Price Performance

Shares of NYSE:RVTY opened at $101.51 on Friday. The company’s 50-day moving average is $104.66 and its 200 day moving average is $101.46. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.77 and a current ratio of 2.07. The company has a market capitalization of $12.54 billion, a P/E ratio of 18.46, a price-to-earnings-growth ratio of 2.67 and a beta of 1.09. Revvity has a fifty-two week low of $79.50 and a fifty-two week high of $132.54.

Revvity Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.28%. Revvity’s dividend payout ratio (DPR) is currently 5.09%.

Insider Transactions at Revvity

In other news, insider Prahlad R. Singh sold 21,217 shares of the stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $104.28, for a total value of $2,212,508.76. Following the sale, the insider now directly owns 92,801 shares of the company’s stock, valued at $9,677,288.28. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. UBS Group downgraded shares of Revvity from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $105.00 to $125.00 in a report on Tuesday, January 16th. Barclays boosted their price target on shares of Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Raymond James upped their price objective on shares of Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Evercore ISI raised shares of Revvity from an “in-line” rating to an “outperform” rating and upped their price objective for the company from $88.00 to $125.00 in a report on Thursday, January 4th. Finally, Stifel Nicolaus upped their price objective on shares of Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a report on Friday, February 2nd. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $118.91.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.